Is IMA or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.96% -34.60% Oncobiologics N/A N/A -291.28%

Is IMA or AVXL more profitable?

Anavex Life Sciences' return on equity of -38.76% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.96% -34.60% Anavex Life Sciences N/A -38.76% -35.01%

Is IMA or FULC more profitable?

Fulcrum Therapeutics' return on equity of -27.80% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.96% -34.60% Fulcrum Therapeutics N/A -27.80% -26.32%

Does the media refer more to IMA or FULC?

In the previous week, ImageneBio and ImageneBio both had 2 articles in the media. Fulcrum Therapeutics' average media sentiment score of 1.45 beat ImageneBio's score of 0.70 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImageneBio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMA or IVVD more profitable?

ImageneBio has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. ImageneBio's return on equity of -38.96% beat Invivyd's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.96% -34.60% Invivyd -138.90% -53.48% -41.56%

Does the media refer more to IMA or IVVD?

In the previous week, ImageneBio and ImageneBio both had 2 articles in the media. Invivyd's average media sentiment score of 0.80 beat ImageneBio's score of 0.70 indicating that Invivyd is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImageneBio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KPTI or IMA?

In the previous week, Karyopharm Therapeutics had 1 more articles in the media than ImageneBio. MarketBeat recorded 3 mentions for Karyopharm Therapeutics and 2 mentions for ImageneBio. Karyopharm Therapeutics' average media sentiment score of 1.28 beat ImageneBio's score of 0.70 indicating that Karyopharm Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImageneBio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ImageneBio (IMA) Competitors

$6.02 -0.09 (-1.47%)

Closing price 04:00 PM Eastern

Extended Trading

$6.03 +0.01 (+0.17%)

As of 04:10 PM Eastern

Compare

IMA vs. OTLK, AVXL, FULC, IVVD, and KPTI

Should you buy ImageneBio stock or one of its competitors? MarketBeat compares ImageneBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ImageneBio include Oncobiologics (OTLK), Anavex Life Sciences (AVXL), Fulcrum Therapeutics (FULC), Invivyd (IVVD), and Karyopharm Therapeutics (KPTI). These companies are all part of the "pharmaceutical products" industry.

How does ImageneBio compare to Oncobiologics?

ImageneBio (NASDAQ:IMA) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Oncobiologics' return on equity of 0.00% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
Oncobiologics	N/A	N/A	-291.28%

In the previous week, ImageneBio and ImageneBio both had 2 articles in the media. Oncobiologics' average media sentiment score of 1.26 beat ImageneBio's score of 0.70 indicating that Oncobiologics is being referred to more favorably in the news media.

Company	Overall Sentiment
ImageneBio	Positive
Oncobiologics	Positive

ImageneBio presently has a consensus price target of $26.50, indicating a potential upside of 340.20%. Oncobiologics has a consensus price target of $6.50, indicating a potential upside of 275.72%. Given ImageneBio's higher probable upside, equities research analysts clearly believe ImageneBio is more favorable than Oncobiologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ImageneBio has higher earnings, but lower revenue than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	80.14	-$45.35M	-$5.79	N/A
Oncobiologics	$1.35M	190.42	-$62.42M	-$1.17	N/A

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 2.2% of ImageneBio shares are held by insiders. Comparatively, 1.8% of Oncobiologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ImageneBio has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

Summary

ImageneBio and Oncobiologics tied by winning 7 of the 14 factors compared between the two stocks.

How does ImageneBio compare to Anavex Life Sciences?

ImageneBio (NASDAQ:IMA) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 2.2% of ImageneBio shares are held by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ImageneBio has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	80.14	-$45.35M	-$5.79	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

ImageneBio currently has a consensus target price of $26.50, indicating a potential upside of 340.20%. Anavex Life Sciences has a consensus target price of $21.33, indicating a potential upside of 777.91%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Anavex Life Sciences' return on equity of -38.76% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
Anavex Life Sciences	N/A	-38.76%	-35.01%

ImageneBio has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

In the previous week, ImageneBio had 1 more articles in the media than Anavex Life Sciences. MarketBeat recorded 2 mentions for ImageneBio and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.87 beat ImageneBio's score of 0.70 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
ImageneBio	Positive
Anavex Life Sciences	Very Positive

Summary

Anavex Life Sciences beats ImageneBio on 8 of the 15 factors compared between the two stocks.

How does ImageneBio compare to Fulcrum Therapeutics?

ImageneBio (NASDAQ:IMA) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Fulcrum Therapeutics' return on equity of -27.80% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

In the previous week, ImageneBio and ImageneBio both had 2 articles in the media. Fulcrum Therapeutics' average media sentiment score of 1.45 beat ImageneBio's score of 0.70 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulcrum Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImageneBio has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 3.01, indicating that its share price is 201% more volatile than the broader market.

ImageneBio presently has a consensus price target of $26.50, indicating a potential upside of 340.20%. Fulcrum Therapeutics has a consensus price target of $8.20, indicating a potential upside of 128.41%. Given ImageneBio's stronger consensus rating and higher probable upside, equities research analysts plainly believe ImageneBio is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 2.2% of ImageneBio shares are owned by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ImageneBio has higher earnings, but lower revenue than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	80.14	-$45.35M	-$5.79	N/A
Fulcrum Therapeutics	$80M	2.99	-$74.88M	-$1.15	N/A

Summary

Fulcrum Therapeutics beats ImageneBio on 9 of the 15 factors compared between the two stocks.

How does ImageneBio compare to Invivyd?

ImageneBio (NASDAQ:IMA) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

ImageneBio has higher earnings, but lower revenue than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	80.14	-$45.35M	-$5.79	N/A
Invivyd	$53.43M	4.42	-$52.49M	-$0.31	N/A

ImageneBio has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. ImageneBio's return on equity of -38.96% beat Invivyd's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
Invivyd	-138.90%	-53.48%	-41.56%

In the previous week, ImageneBio and ImageneBio both had 2 articles in the media. Invivyd's average media sentiment score of 0.80 beat ImageneBio's score of 0.70 indicating that Invivyd is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImageneBio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Invivyd	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImageneBio presently has a consensus target price of $26.50, indicating a potential upside of 340.20%. Invivyd has a consensus target price of $8.00, indicating a potential upside of 899.00%. Given Invivyd's stronger consensus rating and higher probable upside, analysts clearly believe Invivyd is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

ImageneBio has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market.

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 2.2% of ImageneBio shares are held by insiders. Comparatively, 12.3% of Invivyd shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

ImageneBio beats Invivyd on 9 of the 16 factors compared between the two stocks.

How does ImageneBio compare to Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 2.2% of ImageneBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Karyopharm Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

Karyopharm Therapeutics presently has a consensus price target of $17.17, suggesting a potential upside of 71.50%. ImageneBio has a consensus price target of $26.50, suggesting a potential upside of 340.20%. Given ImageneBio's higher probable upside, analysts plainly believe ImageneBio is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

ImageneBio has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-129.02%	N/A	-120.29%
ImageneBio	N/A	-38.96%	-34.60%

In the previous week, Karyopharm Therapeutics had 1 more articles in the media than ImageneBio. MarketBeat recorded 3 mentions for Karyopharm Therapeutics and 2 mentions for ImageneBio. Karyopharm Therapeutics' average media sentiment score of 1.28 beat ImageneBio's score of 0.70 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Karyopharm Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImageneBio	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ImageneBio has lower revenue, but higher earnings than Karyopharm Therapeutics. ImageneBio is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	1.55	-$196.04M	-$15.09	N/A
ImageneBio	$800K	80.14	-$45.35M	-$5.79	N/A

Summary

Karyopharm Therapeutics and ImageneBio tied by winning 8 of the 16 factors compared between the two stocks.

Get ImageneBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMA vs. The Competition

Export

Metric	ImageneBio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$65.10M	$3.68B	$6.85B	$12.45B
Dividend Yield	N/A	2.19%	2.68%	8.43%
P/E Ratio	-1.04	20.98	27.04	24.38
Price / Sales	80.14	311.16	524.25	93.51
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	0.51	8.54	10.80	6.33
Net Income	-$45.35M	$23.83M	$3.59B	$331.02M
7 Day Performance	-0.82%	-3.53%	-2.24%	-1.09%
1 Month Performance	7.12%	6.29%	3.12%	-0.49%
1 Year Performance	-63.38%	48.64%	26.30%	19.90%

ImageneBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMA ImageneBio	2.0316 of 5 stars	$6.02 -1.5%	$26.50 +340.2%	-63.1%	$65.10M	$800K	N/A	70
OTLK Oncobiologics	3.7373 of 5 stars	$1.69 +16.0%	$6.50 +283.7%	-25.1%	$251.71M	$1.35M	N/A	20	Positive News
AVXL Anavex Life Sciences	2.8363 of 5 stars	$2.72 +0.2%	$21.33 +685.5%	-78.8%	$251.70M	N/A	N/A	40	Positive News Upcoming Earnings
FULC Fulcrum Therapeutics	3.5948 of 5 stars	$3.73 -1.2%	$8.20 +120.1%	-54.8%	$248.20M	$80M	N/A	100	News Coverage Positive News
IVVD Invivyd	3.7951 of 5 stars	$0.82 -12.6%	$8.00 +872.1%	+6.6%	$242.46M	$53.43M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMA) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImageneBio (IMA) Competitors

IMA vs. OTLK, AVXL, FULC, IVVD, and KPTI

How does ImageneBio compare to Oncobiologics?

Summary

How does ImageneBio compare to Anavex Life Sciences?

Summary

How does ImageneBio compare to Fulcrum Therapeutics?

Summary

How does ImageneBio compare to Invivyd?

Summary

How does ImageneBio compare to Karyopharm Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMA vs. The Competition

ImageneBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImageneBio (IMA) Competitors

IMA vs. OTLK, AVXL, FULC, IVVD, and KPTI

How does ImageneBio compare to Oncobiologics?

Is IMA or OTLK more profitable?

Does the media refer more to IMA or OTLK?

Do analysts rate IMA or OTLK?

Which has better earnings & valuation, IMA or OTLK?

Do institutionals & insiders believe in IMA or OTLK?

Which has more volatility & risk, IMA or OTLK?

Summary

How does ImageneBio compare to Anavex Life Sciences?

Do institutionals and insiders believe in IMA or AVXL?

Which has higher valuation & earnings, IMA or AVXL?

Do analysts rate IMA or AVXL?

Is IMA or AVXL more profitable?

Which has more risk and volatility, IMA or AVXL?

Does the media refer more to IMA or AVXL?

Summary

How does ImageneBio compare to Fulcrum Therapeutics?

Is IMA or FULC more profitable?

Does the media refer more to IMA or FULC?

Which has more volatility & risk, IMA or FULC?

Do analysts prefer IMA or FULC?

Do institutionals & insiders believe in IMA or FULC?

Which has preferable earnings & valuation, IMA or FULC?

Summary

How does ImageneBio compare to Invivyd?

Which has better valuation and earnings, IMA or IVVD?

Is IMA or IVVD more profitable?

Does the media refer more to IMA or IVVD?

Do analysts rate IMA or IVVD?

Which has more volatility & risk, IMA or IVVD?

Do insiders & institutionals believe in IMA or IVVD?

Summary

How does ImageneBio compare to Karyopharm Therapeutics?

Do insiders and institutionals hold more shares of KPTI or IMA?

Which has more volatility and risk, KPTI or IMA?

Do analysts recommend KPTI or IMA?

Is KPTI or IMA more profitable?

Does the media prefer KPTI or IMA?

Which has higher valuation and earnings, KPTI or IMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMA vs. The Competition

ImageneBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools